The area where the motor neurons and muscles "connect" is called the neuromuscular junction (NMJ). NMJ health and function is a crucial part of the nervous system and highly scrutinized in ALS research. This area has proven itself promising with respect to targeting treatments aimed at stabilizing the connection or even re-establishing lost connections between existing motor neuron and muscle tissue in ALS patients.
We are currently conducting pharmacokinetic and pharmacodynamic experiments to determine an appropriate dosing stratagem to move this project into later-stage preclinical testing, such as survival efficacy screening.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!
Stay up to date with ALS TDI by subscribing to our newsletter today!